Loading...
Searching Database & Compiling the results...
This process involves analyzing complex genetic data and may take a moment.
PDX model details
| PDX ID | 156R |
|---|---|
| Host Strain(and Source) | NSG Source: Monash University |
| Host Strain Immune system Humanized | NO |
| Host Type | Testosterone supplemented |
| Graft Site | Renal |
| Current Generation (* indicates number of generations grown in Castrate host) |
7 |
| Average PDX Generation Time (days +/- SEM) | 269 ± 52 |
| Tumour preparation | Tumor solid |
| Tumour Characterization Technology | Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin | Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed | Routine QA every 2-3 passages |
| Associated meta data | |
| PDX model availability | Yes (fixed, frozen) |
| Governance restriction for distribution | Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements. |
| Pubmed ID | 34413304 |
| Markers | 156R |
|---|---|
| AR | Y |
| PSA | Y |
| PSMA | Y |
| NE | N |
| ERG | N |
This table displays curated CNVs
| PDX ID | Gene Symbol | CNV Log2 | CNV Copy | CNV Call | Experiments name | Platform | Reference genome |
|---|---|---|---|---|---|---|---|
| 156R | NCOR1 | -23.369 | 1.850e-07 | Homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 156R | PIK3R1 | -1.589 | 0.665 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 156R | CDK12 | -0.813 | 1.139 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 156R | BRCA1 | -0.811 | 1.140 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 156R | NCOR1 | -0.783 | 1.162 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 156R | FANCA | -0.778 | 1.166 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 156R | AKT1 | 0.565 | 2.958 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 156R | MET | 0.718 | 3.290 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 156R | BRAF | 0.718 | 3.290 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 156R | EZH2 | 0.718 | 3.290 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 156R | KMT2C | 0.718 | 3.290 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 156R | MYC | 0.743 | 3.346 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 156R | CHD7 | 0.750 | 3.365 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
Clinical Information
| Sample Number | 156R |
|---|---|
| Sample Site | Prostate |
| Sample source | Radical prostatectomy |
| Pathology Tumour Diagnosis | Adenocarcinoma |
| Gleason Score | 9 |
| Primary Gleason Score | 4 |
| Secondary Gleason Score | 5 |
| Tertiary Gleason Score | None |
| ISUP Grade Group | 5 |
| Tumour Grade | pT3b |
| D'Amico Risk Classification | 8 |
| Tumour Volume (in cc) | 28.6 |
| Treatment Prior to Specimen Collection | None |
Patient Information
| Patient Number | 156 |
|---|---|
| Sex | Male |
| Diagnosis | Prostate Cancer |
| PSA at diagnosis (ng/mL) | 16.8 |
| Consent to share data | Yes, subject to ethical review |
| Patient Tumour Collection (Current Model) | |
|---|---|
| Tumour sample ID | 156R |
| Patient Age (binned in 5 year age groups) | 70-74 |
This table displays curated sequence variants
| PDX ID | Gene Symbol | Total Read Depth | Alternate Frequency | Consequence | Exon | GnomAD AF | CADD PHRED score | ClinVar significance | Platform | Experiments Name | Reference | Library Type | Instrument Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 156R | LOXL1 | 260 | 1.0 | Missense variant | '6/7 | 9.75E-05 | 26.4 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 156R | ATRX | 247 | 1.0 | Missense variant | '7/35 | . | 23.4 | Pathogenic | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 156R | SPOP | 229 | 1.0 | Missense variant | '6/12 | . | 24.8 | Likely pathogenic | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 156R | TP53 | 183 | 1.0 | Missense variant | '7/11 | . | 25.3 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 156R | AR | 239 | 0.99 | Missense variant | '1/8 | . | 26.5 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 156R | NEUROG2 | 400 | 0.99 | Missense variant | '2/2 | . | 25.7 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 156R | UGT1A4 | 465 | 0.65 | Missense variant | '1/5 | . | 23.5 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 156R | SPEN | 226 | 0.43 | Missense variant | '11/15 | 0.0003253 | 24.7 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 156R | LATS2 | 192 | 0.4 | Inframe insertion | '4/8 | . | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 156R | ARID2 | 418 | 0.33 | Frameshift variant | '15/21 | . | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 156R | GRIN2A | 332 | 0.28 | Missense variant | '10/14 | . | 28.2 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 156R | NTRK1 | 499 | 0.27 | Missense variant | '17/17 | . | 24 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
No information in Drug dosing Table